Mithra Pharmaceuticals S.A.

Major Shareholding Notification • Dec 19, 2023

Publication of transparency notifications received from The Goldman Sachs Group Inc.

Liege, Belgium, 19 December 2023 – 17:45 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces, in accordance with Article 14 of the Belgian Law of 02 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received on 29 November, 30 November, and 1 December, notifications of transparency from The Goldman Sachs Group, Inc with registered offices at 1209 Orange Street, Wilmington, DE 19801, USA.

The Goldman Sachs Group, Inc. notified Mithra on 29 November 2023 that in the category "% of voting rights related to securities lending," it has dropped below the statutory notificationthreshold of 3% of the 69,108,397 shares currently outstanding on 22 November 2023, resulting in a position of 1.70% (1,175,467 shares) of shares outstanding on that date. Goldman Sachs' "total % of voting rights" did not cross a threshold on that date and was 3.52% (2,431,316 shares) of Mithra's outstanding securities. Previously, The Goldman Sachs Group, Inc. notified Mithra of their "total % of voting rights" position of 3.63% (2,505,414 shares) of Mithra's outstanding securities.

The Goldman Sachs Group, Inc. also notified Mithra on 30 November 2023 that in the category "% of voting rights related to securities lending," it has risen above the statutory notification-threshold of 3% on 24 November 2023. The Goldman Sachs Group, Inc. held 3.48% (2,406,427 shares) of the 69,108,397 shares outstanding on 24 November 2023. Previously, The Goldman Sachs Group, Inc. notified Mithra that on 29 November 2023, their holding was 1.70% (1,175,467 shares) in the category "% of voting rights related to securities lending" of Mithra's outstanding securities. The total % of voting rights held by The Goldman Sachs Group, Inc on 24 November 2023 did not cross a threshold and was 3.48% (2,406,427 shares) of Mithra's outstanding securities.

The Goldman Sachs Group, Inc. also notified Mithra on 6 December 2023 that in the category "% of voting rights related to securities lending," it has dropped below the statutory notification-threshold of 3% on 30 November 2023. The Goldman Sachs Group, Inc. held 1.69% (1,169,936 shares) of the 69,108,397 shares outstanding on 30 November 2023 in the category "% of voting rights related to securities lending." Previously, The Goldman Sachs Group, Inc. notified Mithra that on 30 November 2023, their holding was 3.48 % (2,406,427 shares) in the category "% of voting rights related to securities lending," of Mithra's outstanding securities. The total % of voting rights held by The Goldman Sachs Group, Inc on 30 November 2023 did not cross a threshold and was 3.41% (2,359,668 shares) of Mithra's outstanding securities.

The detailed transparency notifications are available on the Investors section of Mithra website.

For more information, please contact:

Mithra Pharmaceuticals SA

Alex Sokolowski, PhD Head of IR & Communications investorrelations@mithra.com +32 (0)4 349 28 22

Frédérique Depraetere Communications Director info@mithra.com +32 (0)4 349 28 22

About Mithra

Mithra Pharmaceuticals SA (Euronext: MITRA) is a Belgian biopharmaceutical company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill ESTELLE® , Mithra is now focusing on its second product DONESTA® , the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, is headquartered in Liège, Belgium. www.mithra.com

ESTELLE® and DONESTA® are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

News Alerts

Subscribe to our mailing list on investors.mithra.com to receive press releases by email or follow us on social media: Linkedin • X • Facebook